Model N Inc (MODN) 2014 Q4 法說會逐字稿

Greetings, and welcome to the Model N fourth-quarter FY2014 earnings conference call.

(Operator Instructions)

As a reminder, this conference is being recorded. I would now like to turn the conference over to Mr. Greg Kleiner, Investor Relations for Model N. Thank you, Mr. Kleiner. You may now begin.

Thank you. Good afternoon, and welcome to Model N's fourth-quarter FY14 earnings conference call. Joining me today are Zack Rinat, Model N's Founder, Chairman and CEO; and Mark Tisdel, Model N's SVP and Chief Financial Officer. Following their prepared remarks, we will take questions. Our press release was issued after close of market and is posted on our website where this call is being simultaneously webcast.

The primary purpose of today's call is to provide you with information regarding our fourth-quarter FY14 performance, in addition to our financial outlook for our first-quarter and full-year FY15. Commentary made on this call may include forward-looking statements. These statements are subject to risks, uncertainties, and assumptions. Please refer to the press release and the risk factors in documents filed with the Securities and Exchange Commission, including our annual report on Form 10-K, and our quarterly reports on Form 10-Q, for information on risks and uncertainties.

Should any of these risks or uncertainties materialize, or should our assumptions prove to be incorrect, actual Company results could differ materially from these forward-looking statements. In addition, during today's, call we will discuss non-GAAP financial measures. These non-GAAP financial measures, which are used as measures of Model N's performance, should be considered in addition to, not as a substitute for, or in isolation from, GAAP results.

You can find additional disclosures regarding these non-GAAP measures, including reconciliations with comparable GAAP results, in our press release. At times, in response your questions, we may offer incremental metrics to provide greater insight into the dynamics of our business or our quarterly results. Please be advised that this additional detail may be one-time in nature, and we may or may not provide an update in the future on these metrics.

I encourage you to visit our Investor Relations website at investor.ModelN.com to access our fourth-quarter FY14 press release, periodic SEC reports, and the webcast replay of this call, which will be available for the next 45 days. Finally, unless otherwise stated, all financial comparisons in this call will be to our results for the comparable period of our FY13.

With that, let me turn the call over to Zack.

Good afternoon, everyone, and thank you for joining us today. I'd like to start the call with a summary of Q4 and FY14, and then cover our strategy for FY15 and beyond. Mark Tisdel, our CFO, will follow my remarks with details on the financials. Model N executed well in FY14 across vertical, geographies, and functions, demonstrating the tremendous market opportunity for revenue management and the positive results from our core strategic initiatives.

We also saw a transformational shift in our business towards recurring revenue streams throughout the year, a trend we expect to continue going forward, based on a number of factors that I will outline in a moment. Our Q4 results represented another quarter of improved performance as we exceeded our guidance on both the top and the bottom line. Furthermore, our first quarter revenues grew from Q3 2014, marking what we believe was the trough in our revenue. We are confident that we have addressed the sales execution challenges we encountered in FY13 and we expect to return to year-over-year growth in Q1 and FY15 as a whole.

Let me begin with a discussion of some of the highlights from the fourth quarter. In life sciences, we signed several deals, including one with Bristol-Myers Squibb for Revvy Global Price Management, or Revvy GPM. Revvy GPM is a SaaS offering based on force.com that enables life sciences companies to manage their prices on a global basis. Leveraging Revvy GPM, BMS will enable worldwide collaboration and transparency for their global organization. Revvy GPM will enable BMS to maximize their revenue by reducing price and revenue erosion via best practices and sophisticated analytics.

In the high-tech vertical, I wanted to highlight two new SaaS deals we signed with industry icons Intel and Fairchild Semiconductors. For Intel, we signed a new relationship with the Internet of Things, or IoT Group, as they were looking for a sophisticated and agile revenue management platform to help scale their business. Our revenue management enterprise solution will enable the IoT Group to price and quote based on the bundle of silicon, software, and services while managing incentives such as rebates and market development funds. In addition, they will be able to analyze and optimize their revenue via our revenue management intelligence analytics offering.

With Fairchild, we signed a deal to manage their global revenue, leveraging both our revenue management enterprise and revenue management intelligent solutions. Fairchild plans to replace their legacy systems with an end-to-end revenue management platform from Model N enable them to leverage best practices to manage both direct and channel sales on a global basis. By standardizing and coordination to revenue management functions, Fairchild will be able to maximize the revenues and gross margins by reducing revenue leakage.

We also signed several deals for our Revvy CPQ product, including RamSoft, a Canadian software and services company focused on the healthcare industry. RamSoft was looking to standardize and simplify their sales proposal, but also to drive cross selling by offering optional features automatically in the proposal process. By adopting Revvy CPQ, RamSoft will be able to maximize their revenues [through] opportunity by leveraging a sophisticated pricing model based on a variety of inputs such as the number of patient studies, service options, and product selection.

We are also pleased to announce that David Bonnette, Chief Executive Officer of Lanyon, his joined our Board of Directors. David has served as a variety of executive roles in the software industry over his nearly 20 years career. Before joining Lanyon, David was CEO of BigMachines, a leader in the CPQ market that was acquired by Oracle.

Overall, FY14 was a year of tremendous progress for Model N as we improve our go-to-market process, grow our bookings, and took several steps to further transform our business to a recurring revenue model. Importantly, we believe that we have an opportunity to continue the shift to recurring revenues, in FY15 and beyond, based on the following four factors. First, increased acceptance of SaaS as a delivery vehicle within the large life sciences companies, along with some new revenue management as a service offering.

Second, further penetration of the midmarket opportunity of the life sciences industry with SaaS is the preferred delivery model. Third, increased percentage of other revenues from the technology vertical where SaaS is widely accepted in the delivery model. And, finally, Model N products and offering [that our mark] is SaaS only, such as our Revvy family of products. Let me discuss each item in a little more detail.

We are seeing an increased interest from large life sciences companies for such versions of our product. In addition, we have launched several new revenue management as a service offering designed to help our current customers migrate their existing on-premise implementations to SaaS, including efforts for custom upgrades, application management, and complete migration packages. FY14 demonstrated that there is a significant market opportunity in the midmarket for life sciences where Model N has traditionally had a limited presence, and SaaS is by far the preferred delivery vehicle.

In Q4, we officially launched Express, a solution providing a comprehensive preconfigured SaaS revenue management solution. Express is built on the best practices we have gathered over the last 14 years working with the largest brains in life sciences, and is optimized for midsize pharma and med-tech companies. In our high-tech vertical, we announced at Dreamforce 2014 our Revvy Sales offering, the first CRM solution specifically designed for semiconductors and component manufacturers.

Revvy Sales was built on the partnership between salesforce.com and Model N, combining salesforce.com leading CRM solutions and Model N's unique vertical expertise. Unifying CRM with revenue management created a powerful combination and significantly increased the total addressable market for Model N. We anticipate the opportunity to create this combined offering, as well as the up-sell opportunity for Revvy Sales in our installed base, will enable us to increase the percentage of our business overall from the high-tech vertical and, hence, the percentage of recurring revenues as well.

Finally, the growth of our Revvy family of products built on force.com. I mentioned our Revvy GPM and our Revvy Sales application earlier. In addition, we expect further growth from our Revvy CPQ of considerable price and quoting solution. We announced, at Dreamforce, Revvy CPQ for med-tech, a solution designed specifically for that market segment as well as a program to replace legacy CPQ solutions with Revvy CPQ.

We expect these four factors to enable our SaaS and maintenance revenue to grow faster than our life sciences and implementation revenue, once again in FY15. And we intend to focus on continuing this [pathway] going forward.

Overall, I am encouraged by the progress we have made throughout the year in our go-to-market execution. Model N has made, and will continue to make, significant investments in sales and marketing. These investments made solid contributions to the results of Q4 and FY14. And we expect them to make even bigger contributions in the foreseeable future as we continue the transformation of our business model to include more recurring revenues.

The people and processes we have put in place have helped to increase the consistency of our performance and the positive outlook for the future. In addition, our enhanced go-to-market capabilities and living products suite position us well for continued success. I am confident that we have turned the corner in our sustained growth trajectory.

Let me now turn the call over to Mark to discuss our financial results and guidance in more detail.

Thank you, Zack. Total revenues for the fourth quarter were $20.3 million, above our guidance range of $19.5 million to $20 million. This compares to $27.8 million in total revenue in the year-ago period. The year-over-year decline was driven by the sales execution issues discussed in recent periods, with particular concentration in the license and implementation line.

However, as our guidance will outline in a moment, we expect the recent improvements in our execution will allow the business to return to year-over-year growth in the first quarter, as well as the upcoming fiscal year. Within total revenue, license and implementation revenues were $7.9 million, and SaaS and maintenance revenues were $12.4 million for the quarter. In the fourth quarter of FY14, the amount of revenue coming from existing customers within revenue in each of the last four quarters was $72.5 million, compared to $92 million for the fourth quarter of 2013. We ended the year with 80 customers, compared to 69 at the end of FY13.

Before I move on to profit and loss items, I want to remind you that my commentary will be based on non-GAAP results. A reconciliation of non-GAAP to GAAP results provided with our earnings press release issued earlier today. Gross profit for the fourth quarter was $11.8 million, compared to $16.3 million in the fourth quarter of FY13. Similar to recent quarters, gross profit in this quarter included an impact of roughly $400,000 from the amortization of capitalized software that began upon the launch of our Revvy CPQ offering. Overall gross margin in the quarter was 58.4%, compared to 58.6% in Q4 of last year.

Research and development expense was $4 million, compared to $3.8 million in the fourth quarter of FY13. We are continuing to invest in our new products, but did begin to capitalize the expenditures related to Revvy Sales, which amounted to approximately $400,000 in the quarter.

Sales and marketing expense was $6.8 million, compared to $4.4 million in the year-ago period. This increase was driven by our continued investment in sales and marketing personnel, marketing program spend, and the marketing expenditures supporting our involvement in Dreamforce this year. G&A expense was $4.1 million, compared to $4 million in Q4 of FY13. Operating loss to the period was $3.1 million, compared to an operating profit of $4 million in Q4 of last year and above our guidance of an operating loss of $4 million to $4.5 million.

Net loss in the fourth quarter was $3.3 million, compared to net income of $3.8 million in the fourth quarter of FY13. This produced a net loss per share of $0.13, based on a share count of 24.9 million shares, compared to a net income per share of $0.15, based on a fully diluted share count of 25.9 million shares in the fourth quarter last year. This is above our guidance of a net loss of $0.16 to $0.18 per share.

Adjusted EBITDA for the fourth quarter was negative $2.3 million, compared to positive $4.5 million in the year-ago period. We ended the fourth quarter with $101 million of cash and cash equivalents, down slightly from $103.2 million at the end of the third quarter. At the end of the fourth quarter, our accounts receivable balance was $15.2 million and our total deferred revenue was $26.5 million. As mentioned previously, we believe our accounts receivable and deferred revenue balances are not a meaningful indicator of the business activity during any particular quarter, and the timing of the invoices under contract impact these items as we do not bill all of our customers up front for total contract fees.

For the fourth quarter, cash flow used by operations was $2.6 million, which, after considering CapEx of $300,000 and $400,000 of capitalized software, produced a negative free cash flow of $3.3 million. This compared to cash provided by operations of $300,000 in the fourth quarter of last year, which, after considering $600,000 of CapEx and $1 million of capitalized software, produced a negative free cash flow of $1.4 million. Similar to prior commentary in regards to our receivables and deferred revenue balances, there can be some quarter-to-quarter variability in our cash flow as it is impacted by the timing of invoicing under our contracts.

Moving on, let me now outline our guidance for the first quarter and full FY15. For the first quarter ending December 31, we expect total revenues to range from $21.6 million to $21.9 million. Non-GAAP loss from operations in the range of $2.5 million to $2.8 million. This would lead to a non-GAAP net loss per share in the range of $0.10 to $0.11, based on a weighted average share count of 25.3 million shares. For FY15 as a whole, we expect total revenues to range from $92 million to $93.5 million, or growth of 13% to 14% for the year as a whole.

As Zack mentioned earlier, we do expect that revenues from our SaaS and maintenance lines will grow faster than the revenues from our license and implementation line in the upcoming year, resulting in further improvement in the percentage of revenue coming from recurring sources. We expect non-GAAP loss from operations in a range from $8 million to $9.5 million. This would lead to a non-GAAP net loss per share in the range of $0.31 to $0.37, based on a weighted average count of 25.9 million shares.

In addition to formal guidance, I do want to add one comment regarding our past profitability. It is our current expectation that we will break even on an adjusted EBITDA basis in the fourth quarter of FY15 and make further improvements in our profitability in FY16. As mentioned previously, we have continued to invest our return to growth in recent periods but expect to see increased leverage on these investments as we move forward.

In summary, we have strong confidence in our outlook based on the recent pace of our business, our current backlog and pipeline, along with our improved ability to execute consistently. We believe that we have put the right pieces in place to continue the transformation of our business and insurability grow and move towards profitability on a sustained basis.

We will now open the floor for your questions.

(Operator Instructions)

Sterling Auty, JPMorgan.

I wanted to go into a couple of questions. Actually first on that last comment about the adjusted EBITDA profitability in the fourth quarter. How do we think about that relative to does that mean that perhaps you would be cashflow positive in that quarter as well?

It's possible. As far as -- Sterling, this is Mark. As far as the matching of the cash flow and the EBITDA, if you look at it over a four-month or four-quarter rolling period, you would expect to see that they would match up very closely. Within the quarter itself, there could be some variety of comparability, but we do expect it would be very similar results in Q4.

But I would imagine for the full year show cash flow burns?

We would expect to be burning cash in FY15. Correct

Okay, and on the shift that you are undergoing in terms of move for the recurring and SaaS, any sense -- I know you told us it's going to grow faster, but any sense of what the mix of bookings look like or what the mix of revenue might look like exiting there?

Yes, so Sterling, what we see as a outline is a rapid shift towards SaaS and to recurring revenues. And we see right now a quite the fast deduction for SaaS, even if there the high end of life sciences, and definitely is the preferred model in high-tech and in the midmarket.

We also have a set of offerings right now that our revenue management as a service that we offer both to new customers as well as to the existing installed base. And because of this, we expect that we are going to continuously to see this -- notice this shift. We don't want to give a specific kind of no numbers, but we see it definitely as the bigger part of our bookings and revenue moving forward.

Okay, and last question from my side. Big transition here, you made a lot of changes, just curious where you are in terms of sales management and sales rep. Are all the roles filled? Are you comfortable with the force that you have going into the new fiscal year, or is there any further changes that are necessary?

Yes, so we made a few changes in the organization, both structurally and also size-wise. We made investment in sales and in marketing, as you can see from our financials. As I mentioned in my comments, we saw solid performance from the sales organization that contributed to the results of Q4 into the year. And now that we have these people on board for some times, we feel that they're going to make much greater contribution when they have a full year to excel for the Company where they are fully ramped up.

This is also true in the Management side of the business and across the board in all of our way, kind of the go-to-market functions. So I feel that we have both the structure, the organization, and the leadership to leverage on what we did in FY14 moving forward.

Great. Thank you.

Nandan Amladi, Deutsche Bank.

Zack, first question for you. I know you made reference to the fact that you plan to add sales capacity in FY15. How much did you grow sales capacity in FY14 and what is the plan for 2015?

So we do not give the specific on the number of sales that people did, but again if you look at the financials on sales and marketing, you can notice that we made some pretty significant investment. And I want to say something more than that, that the people that we had to deliver on FY15, they are basically in their seats in the beginning of the year.

So that is something that we did in -- specifically in the second half of FY14 in order to ensure that we have the capacity to move it forward. And I want to say this is not just in the United States. We also have the capacity in Europe and we also have the right leadership both in the Americas and in Europe.

We augment this also on the [vals] aspects of the go -- to go to market. So one of the things that we can get from this also is that Model N, when we started the fiscal year we had basically the full capacity to deliver on the guidance that Mark outlined.

Okay, but you do plan to add more salespeople through the year in FY15?

Sure, as we look at what it is that we are going to need for FY16 and beyond, yes, we will add more capacity. But I want to make sure that you know that we do not depend on any person we're going to add this year in order to deliver the guidance.

Understood. Okay. And one other question. In terms of your -- since you're expanding more meaningfully into the tech vertical, what is your emphasis on the land versus expand also because your revenue mix is shifting from license and implementation towards SaaS? How should we think about the trajectory of both the license and subscription business but also relative to life sciences versus other verticals?

So you have in the outline, we are very excited about landing both Intel and Fairchild as customers. And both of them are SaaS deals. And SaaS is by far the accepted delivery model for high-tech companies, including some of the largest ones such as Intel. So this is one aspect of high tech.

The second aspect of this is that the product that we announced at DreamForce that we are going to be a genuine developer late in the quarter in December and Revvy Sales, the first CRM solution designed for semiconductors and component manufacturing is a product that we can also go and lend and expand to the installed base as well as sell to other companies that are interested in CRM.

So we believe that that's going to have an acceleration of our revenue in high-tech because it's a solution that is a combination between sales force, sales cloud, and that Model N vertical expertise. It's designed with an effort industry and we had just tremendous acceptance to this product at Rainmaker, and before this.

So that’s going to accelerate also high-tech and also accelerate the percentage of recurring revenue for the Company because it's only offered as a multi-tenant SaaS -- kind of a SaaS platform. So this combination of these two things, A, you are going to see high-tech going faster. It's going to be a higher percentage of our revenue and hence is going to be a higher percentage of recurring revenue for the Company.

Thank you.

Tom Roderick, Stifel.

Zack, I was hoping you could talk a little bit more about the Revvy GPM product, the global price management. I think you mentioned you had a win with Bristol-Myers Squibb in the quarter and as a product, we haven't heard a ton about, would love to hear just a little bit more about some of the key competitors you bump up in that market, what the ASPs look like, and any element of differentiation that really sort of standout in the product line there.

Absolutely. The global price management is a multi-tenant SaaS platform that we introduced on the force.com platform It's a product that enables the life sciences companies, both the pharmaceutical and medical device, to manage their prices on a global basis.

The challenge that these companies face, they start with the notion of reference prices. Without getting to too many details, in the last decade or so, countries started to benchmark the healthcare system of other countries in order to ensure that they pay the lowest price. For example, the German government will benchmark 15 other countries, including Greece and Turkey and others, in order to ensure competitiveness of the prices, and that really forced these companies to ensure that they don't let the local decisions to impact the global pricing.

For example, somebody can make a decision right now in Greece to reduce price, but it's going to impact 50 other countries in terms of prices. Furthermore, it also pushes them to really think about the way that they introduce drugs and medical device to the market because how you think about the sequence makes a big difference. We have a product that we designed also with and for the industry. We are very proud about the customers that we have.

We have icons of the industry, companies like Jensen, like [MV], like Gilead, like AstraZeneca, and now Bristol-Myers Squibb, and others currently on this platform. And we took a very different approach. We took a strategic long-term and investment approach in our R&D, and we believe that we have highly differentiated product and we tend to compete in this market with small consulting companies that have a higher content of services and a low part of product but they are still competitive in the market.

Perfect. Perfect. Thank you. That's great detail. One follow-up question just to stick on the product set here. CPQ is something that I guess we are getting closer to a year since you announced it and launched it. What are we seeing in the CPQ market?

It seems like that's a hotter space in general in pricing and revenue optimization. Anything in particular that's driving that? And do price points hold up at the same level there as for the core product set?

That's kind of a long discussion, but the CPQ market is a growing market. Look at statistics from Gartner. They expect that this market is growing from 15% to 20% a year. It's a product. It's also a market that is highly segmented. It's highly segmented by geographies, by industries, by technologies, and kind of known others.

Our belief also is that CPQ is an integral part of revenue management as it's always been as part of our solution. And furthermore, we believe that we have unique competitive advantage.

At DreamForce, we announced Revvy CPQ for medical device, and what it is, enabling actually customers and prospects in medical device to enable the research organization to configure, to price, and to quote but they also have the ability to price based on contracts, based on real prices, based on terms that they already negotiate and actually get in the hands of the salesperson, the analytics and the actionable items that they need to go and to drive it.

So we plan to be a player in the market and more than this, we plan to use it as a vehicle to augment our revenue management offering.

Perfect. Last quick one from me. Gross margins look like they are trending up here, at least in the most recent quarter. What's the right way to think for that trend line as we move throughout the next fiscal year here?

Hello, Tom. It's Mark. So, yes, in the last quarter in Q4, we did see a trend up for the line two gross margins, like line one was relatively flat quarter over quarter. We do expect as we go forward, as we've talked about in the past, that we would be able to leverage our investment in the line two and be able to sequentially increase gross margin over time. So I would believe in the long term, we would expect to see that growth towards the 60% as we've talked historically about. I wouldn't necessarily expect every quarter we would see a significant increase, but we would see that over time.

That's great. Thank you, guys, for the help. Appreciate it.

Owen Hyde, Pacific Crest.

It's Owen on for Brendan. I just wanted to follow up on an earlier question. You guys mentioned you'd been adding a lot of sales folks and it seems like some of the results came through this quarter, but I was wondering how long do you think it would take one of these salespeople to become fully productive, operating at peak capacity in terms of months?

When you look at the practical outcomes, the salespeople that we had in the second half of the year did all contribute to the results of Q4. So we saw a good kind of a result within a relatively short kind of a period of time from the sales organization and we started to recruit earlier in the year because we wanted these people to be in their seats and fully productive in kind of the beginning of the (inaudible). So when you look at this bottom line, it's that we have the sales force and the capacity to meet them and the guidelines that Mark, kind of outlined and we feel confident in our ability to bring new salespeople and get them productive as well.

Perfect. Thank you. And when you guys look at the pipeline for the coming year, any specific areas geographically industrywide that may have changed? Any particular areas of strengths or weaknesses?

I would say that when you look at the funnel and the pipeline and it's relatively similar to what we saw in kind of from in the past. When you look at the areas that I feel right now are stronger, I would say in life sciences, definitely global price management, the broader analytic capabilities, and in medical device, the ability to integrate the sales organization via CPQ.

And then in high-tech, I would say Revvy Sales, the CRM solution, we see a great interest and we have a bundle that combined both CRM and revenue management that we call CRM square that is also targeted to market, so also this has a lot of lot of interest as well.

Perfect. That's all I had. Thanks, guys.

Brian Peterson, Raymond James.

You guys referenced pretty strong bookings activity earlier this year, and I'm just curious how should we think about backlog coverage relative to your FY15 outlook maybe versus the prior couple of years?

Hello, Brian. It's Mark. Thanks for the question. We have very strong coverage going into FY2015 relative to our 2014 backlog. It's certainly a metric that we track very closely, and we are at the high end of where we have entered previous years.

Okay. That's helpful. And I appreciate the color on the mix for next year, but would we expect license and implementation sales to be up next year or do you think they could actually be down?

We would expect license and implementation -- I'm going to speak to revenue versus bookings, but I guess they can go hand-in-hand. We would expect license and implementation dollars to be up year over year.

Okay. Thank you.

Scott Berg, Northland Capital Markets.

Hi, Zack and Mark. Congrats on a good quarter here. A couple quick ones for me. Zack, as the SaaS delivery model becomes more important to your overall operations operating model, how much do you see customers moving from the existing on premise platform to the SaaS platform and then does that become more of a push -- you pushing them to that model or a pull where they try to get there at their own pace?

We always had the philosophy that we need to provide our customers with choices. While our vision is always SaaS and recurring revenues, we understand that our customers, especially the large customers in the life sciences have their own strategies, and we offer a solution that enables them to go on-premise on SaaS and actually to transform. What we see right now is accelerated demand towards the SaaS and we see it in a couple of different ways.

So what we did, we introduced a service, several offerings, a revenue management as a service both to new customers and to the installed base that enable them to take a measure of the steps towards the full SaaS. And we see an enormous positive feedback from the installed base on this.

You have to remember that because of the relationship that we have with the customers, because we work with them for a long period of time, because they think about us as a strategic partner, we had discussions with them over a very long period of time and we actually developed this solution based on their input. So I feel that they are moving in this direction and I feel right now that it's becoming to be more of a pull than a push.

Okay, great. And then the last question for me, I guess, is around your growth priorities, your investment priorities for 2014. What is the right way to think about them? Is this more of a sales year trying to accelerate from what appears to be good sales in 2014 or is there a balanced approach with the products for the year?

I would say it's more of a balanced approach than just a sales and marketing. As a Company, we are very committed to provide our customers with innovative solutions. We see opportunities come to our way and when we see opportunities like the one that we saw with Revvy Sales, we believe that it's an investment that is going to yield very high returns to the Company and to our shareholders.

So it's a balanced approach, and when you look at the previous year, we made big investments in sales and marketing. We plan to continue to make them but it's a balanced investment also with R&D and the product.

Great. That's all I have. I will jump in the queue. Thank you.

Thank you. I would now like to turn the floor back over to Mr. Rinat for any closing remarks.

Thank you all of you for joining us today. I'm very pleased with how we closed the FY14, and we have improved confidence in our ability to deliver consistent growth in the future. We remain focused on executing on our strategic initiatives and capitalizing on the tremendous opportunity that is in front of us. I'd like to thank all of you for your interest in Model N, and we look forward to speaking with you again soon. Thank you.

Thank you, ladies and gentlemen. This does conclude today's teleconference. You may disconnect your lines at this time and thank you for your participation.